Brainstorm Cell Therapeutics Inc. (BCLI)

factsheet Factsheet
  • Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $18 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-15 Mln

Brainstorm Cell Therapeutics Inc. (BCLI) Share Price

$0.37

As on 28-Feb-2024 16:00 EST

up-down-arrow $0.000.99%

  • Prev Close info

    $0.36

  • Day's Openinfo

    $0.37

  • Today's Highinfo

    $0.37

  • Today's Lowinfo

    $0.35

  • Today's Volumeinfo

    445,823

  • 52 Week rangeinfo

    $0.13 - 3.46

Please wait...

Brainstorm Cell Therapeutics Inc. (BCLI) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Brainstorm Cell Therapeutics (BCLI)
34.29 15.65 57.95 -84.33 -55.14 -37.93 -21.43
S&P BSE Sensex
0.09 2.27 9.60 21.95 13.77 15.03 13.17
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 28-Feb-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Brainstorm Cell Therapeutics (BCLI)
-83.35 -59.00 -11.60 5.72 20.56 -9.39 54.33
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Brainstorm Cell Therapeutics Inc. (BCLI) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Brainstorm Cell Therapeutics Inc. (BCLI)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Brainstorm Cell Therapeutics Inc. (BCLI)

        President & CEO

        Mr. Chaim Lebovits

        Co-Chief Executive Officer

        Dr. Stacy R. Lindborg Ph.D.

        Headquarters

        New York, NY

        FAQs for Brainstorm Cell Therapeutics Inc. (BCLI)

        The total asset value of Brainstorm Cell Therapeutics Inc. (BCLI) stood at $ 12 Mln as on 30-Sep-23

        The share price of Brainstorm Cell Therapeutics Inc. (BCLI) is $0.37 (NASDAQ) as of 28-Feb-2024 16:00 EST. Brainstorm Cell Therapeutics Inc. (BCLI) has given a return of -55.14% in the last 3 years.

        Brainstorm Cell Therapeutics Inc. (BCLI) has a market capitalisation of $ 18 Mln as on 28-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Brainstorm Cell Therapeutics Inc. (BCLI) is 65.82 times as on 28-Feb-2024, a 21.09% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Brainstorm Cell Therapeutics Inc. (BCLI) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Brainstorm Cell Therapeutics Inc. (BCLI) and enter the required number of quantities and click on buy to purchase the shares of Brainstorm Cell Therapeutics Inc. (BCLI).

        Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Address: 1325 Avenue of Americas, New York, NY, United States, 10019

        The CEO & director of Mr. Chaim Lebovits. is Brainstorm Cell Therapeutics Inc. (BCLI), and CFO & Sr. VP is Dr. Stacy R. Lindborg Ph.D..

        The promoters of Brainstorm Cell Therapeutics Inc. (BCLI) have pledged 0% of the total equity as on Sep-23.

        Brainstorm Cell Therapeutics Inc. (BCLI) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Brainstorm Cell Therapeutics Inc. (BCLI) was $-15 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $17.58 Mln
        • Revenue (TTM)revenue-information $-0.34 Mln
        • Earnings (TTM) earning-information $-15.41 Mln
        • Cash date-information $1.42 Mln
        • Total Debt info $2.89 Mln
        • Insider's Holding 17.61%
        • Liquidity liquidity High
        • 52 Week range week-range $0.13 - 3.46
        • Shares outstanding share-outstanding 48,981,600
        • 10 Years Aggregate:

          CFO: $-146.35 Mln

          EBITDA: $-141.12 Mln

          Net Profit: $-161.68 Mln

        About The Company

        • IPO Date 28-Aug-2003
        • President & CEO Mr. Chaim Lebovits
        • Co-Chief Executive Officer Dr. Stacy R. Lindborg Ph.D.
        • Listing key-listing NASDAQ: BCLI
        • Country United States
        • Headquarters headquarters New York, NY
        • Website website https://www.brainstorm-cell.com
        • Business

          Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy...  platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. Address: 1325 Avenue of Americas, New York, NY, United States, 10019  Read more

        share-fund-plan-icon